Summary
GlobalData has released its pharma report, “Schizophrenia - Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Schizophrenia Market. The report identifies and analyses the key companies shaping and driving the global Schizophrenia market. The report provides insight into the competitive Schizophrenia landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData’s team of industry experts.
*This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase.
Scope
- Investigation of current and future market competition for Schizophrenia
- Competitor assessment
- Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
- Strategic assessment of Schizophrenia sector through market impact analysis, future market scenario and company analysis
Reasons to buy
- Gain a high level view of the trends shaping and driving Schizophrenia market
- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
- Create an effective counter-strategy to gain a competitive advantage against those currently in the market
- What’s the next big thing in the global Schizophrenia market landscape? Identify, understand and capitalize
Companies Mentioned
Alkermes
Dainippon Sumitomo
Eli Lilly
Intra-Cellular Therapies
Janssen
Lundbeck
Minerva Neurosciences
Otsuka
'
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 5
2 Introduction 6
2.1 Catalyst 6
2.2 Related Reports 7
3 Market Outlook 8
3.1 Global Markets 8
3.1.1 Forecast 8
3.1.2 Drivers and Barriers - Global Issues 12
4 Current and Future Players 13
4.1 Overview 13
4.2 Trends in Corporate Strategy 16
4.3 Company Profiles 18
4.3.1 Alkermes 18
4.3.2 Dainippon Sumitomo 20
4.3.3 Eli Lilly 23
4.3.4 Intra-Cellular Therapies 25
4.3.5 Janssen 27
4.3.6 Lundbeck 30
4.3.7 Minerva Neurosciences 33
4.3.8 Otsuka 35
5 Appendix 39
5.1 Bibliography 39
5.2 Abbreviations 81
5.3 Methodology 87
5.4 Forecasting Methodology 87
5.4.1 Diagnosed Schizophrenia Patients 87
5.4.2 Percent Drug-Treated Patients 88
5.4.3 Launch and Patent Expiry Dates 88
5.4.4 General Pricing Assumptions 89
5.4.5 Individual Drug Assumptions 90
5.4.6 Generic Erosion 105
5.4.7 Pricing of Pipeline Agents 105
5.5 Primary Research - KOLs Interviewed for this Report 107
5.6 Primary Research - Prescriber Survey 109
5.7 About the Authors 110
5.7.1 Analyst 110
5.7.2 Therapy Area Director 111
5.7.3 Epidemiologist 111
5.7.4 Managing Epidemiologist 111
5.7.5 Global Director of Therapy Analysis and Epidemiology 112
5.8 About GlobalData 113
5.9 Disclaimer 113
1.1 List of Tables
Table 1: Schizophrenia Market - Drivers and Barriers, 2015-2025 12
Table 2: Key Companies in the Schizophrenia Market in the 7MM, 2015 14
Table 3: Alkermes’ Schizophrenia Portfolio Assessment, 2015 19
Table 4: Alkermes SWOT Analysis in Schizophrenia, 2015-2025 20
Table 5: Dainippon Sumitomo’s Schizophrenia Portfolio Assessment, 2015 22
Table 6: Dainippon Sumitomo SWOT Analysis in Schizophrenia, 2015-2025 23
Table 7: Eli Lilly’s Schizophrenia Portfolio Assessment, 2015 24
Table 8: Eli Lilly SWOT Analysis in Schizophrenia, 2015-2025 25
Table 9: Intra-Cellular Therapies’ Schizophrenia Portfolio Assessment, 2015 26
Table 10: Intra-Cellular Therapies SWOT Analysis in Schizophrenia, 2015-2025 27
Table 11: Janssen’s Schizophrenia Portfolio Assessment, 2015 29
Table 12: Janssen SWOT Analysis in Schizophrenia, 2015-2025 30
Table 13: Lundbeck’s Schizophrenia Portfolio Assessment, 2015 32
Table 14: Lundbeck SWOT Analysis in Schizophrenia, 2015-2025 33
Table 15: Minerva Neurosciences’ Schizophrenia Portfolio Assessment, 2015 34
Table 16: Minerva Neurosciences SWOT Analysis in Schizophrenia, 2015-2025 35
Table 17: Otsuka’s Schizophrenia Portfolio Assessment, 2015 37
Table 18: Otsuka SWOT Analysis in Schizophrenia, 2015-2025 38
Table 19: Key Launch Dates 88
Table 20: Key Patent/Exclusivity Expiries 89
Table 21: High-Prescribing Psychiatrists (Non-KOLs) Surveyed, By Country 109
1.2 List of Figures
Figure 1: Global Sales for Schizophrenia by Region, 2015-2025 10
Figure 2: Global Sales for Schizophrenia by Drug Class, 2015-2025 11
Figure 3: Global Sales of Products for Schizophrenia by Company, 2015-2025 15
Figure 4: Company Portfolio Gap Analysis in Schizophrenia, 2015-2025 16
